Meda acquires five GlaxoSmithKline OTC products for the US market
This article was originally published in Scrip
Executive Summary
Sweden's Meda acquired two more OTC drugs for the US market from GlaxoSmithKline for SEK180 million ($27 million) at the beginning of January after buying three US OTC products for SEK235 million in December. The acquired products were Vivarin (caffeine), the anti-anaemics Feosol and Palafer (iron salts), the vitamin mixture Geritol and Contac (pseudoephedrine hydrochloride), a treatment for a blocked nose and sinus congestion associated with allergies, colds and flu. Their combined annual sales in the US are worth around SEK180 million.